UK DIRECTOR DEALINGS SUMMARY: 888 CEO Sells GBP780,000 In Shares
UK DIRECTOR DEALINGS SUMMARY: 888 CEO Sells GBP780,000 In Shares
Read moreThu, 29th Oct 2020 16:04
UK DIRECTOR DEALINGS SUMMARY: 888 CEO Sells GBP780,000 In Shares
Read moreUK TRADING UPDATE SUMMARY: Mereo To Delist From AIM Amid Nasdaq Focus
Read moreIN BRIEF: Tiziana To Start Brazil Clinical Trial For Covid-19 Patients
Read moreUK EARNINGS SUMMARY: City Pub In Signs Of Recovery After Tough Interim
Read moreUK Shareholder Meetings Calendar - Next 7 Days
Read moreIN BRIEF: Tiziana To Kick Off Clinical Study On Foralumab
Read moreTiziana Plans 2020 London IPO Of StemPrintER, SPARE Assets
Read moreIN BRIEF: Tiziana Life Sciences Gets US Patent On TZLS-501 In Covid-19
Read more(Sharecast News) - Biotechnology company Tiziana Life Sciences announced on Monday that the United States Patent and Trademark Office (USPTO) has granted a patent for methods and use of fully human monoclonal antibody 'TZLS-501' that recognised both IL-6 receptor (IL-6R) and IL-6 receptor complex with IL-6 (IL-6R/IL-6) for prophylactic and therapeutic intervention for human diseases.
Read moreTiziana Life Sciences Gets US Patent For Milciclib In Cancer
Read moreIN BRIEF: Tiziana Gets US Patent For Foralumab As Crohn's Treatment
Read moreUK TRADING UPDATE SUMMARY: Airtel And Telkom Abort Kenya Combination
Read moreUK TRADING UPDATE SUMMARY: Brickability Recovering Well From Pandemic
Read more(Sharecast News) - Biotechnology company Tiziana Life Sciences has signed agreements with four contract research organisations, it announced on Tuesday, to expedite the clinical development of 'TZLS-501' - a novel, fully human anti-interleukin-6 receptor (anti-IL6R) monoclonal antibody (mAb) for the treatment of Covid-19 patients.
Read more